Looking Beneath The Surface In Atopic DermatitisTargeting Immune Dysregulation and Delivering Comprehensive Care
Arkwright PD, et al. J Allergy Clin Immunol Pract. 2013;1(2):142-151
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. May 2017. [Epub ahead of print].
Eichenfield LF, et al. Pediatrics. 2015;136(3):554-565.
Margolis JS, et al. JAMA Dermatol. 2014;150(6):593-600.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, et al. J Am Acad Dermatol. 2016;75(3):494-503.
Patel D, Jahnke MN. Ped Dermatol. 2015;32(6):792-796.
Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.
Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults.
Simpson EL, et al. J Am Acad Dermatol. 2016;74(3):491-498
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Silverberg JI, Greenland P. J Allergy Clin Immunol. 2015;135(3):721-728.
Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study.
Silverberg JI, Silverberg NB. J Allergy Clin Immunol. 2014;133(4):1041-1047.
The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.
Whiteley J, et al. Curr Med Res Opin. 2016;32(10):1645-1651
Clinical Insights Into Atopic Dermatitis Pathogenesis
Narrated by Jeffrey M.Weinberg, MD
Targeting Immune Dysregulation and Delivering Comprehensive Care
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
New Strategies to Target Remission and Individualize Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates and Discussions About Pustular Disease Subtypes
Debates & Discussions on the Evolving Role of JAK Inhibitors
Collaborative Care for Better Patient Outcomes
Debates and Discussion About Managing Moderate-To-Severe Disease
The Evolving Role of JAK Inhibitors